SCHEMBL16199754

SCHEMBL16199754

CCCCCCCCCCCCCCC[C@H](O)[C@@H](NC(C)=O)C(=O)OC

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ZDHHC7 Q9NXF8 1/20 0.51
ABCB1 P08183 1/20 0.51
PLA2G2A P14555 2/20 0.46
PLA2G2C Q5R387 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
BIRC2 Q13490 1/20 0.44
ASAH1 Q13510 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
PLA2G4A P47712 1/20 0.41
GPR84 Q9NQS5 3/20 0.41
SPHK1 Q9NYA1 1/20 0.41
FFAR1 O14842 1/20 0.41
SIRT6 Q8N6T7 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9731631 1.00 ZDHHC7 (0.51) ZDHHC7ABCB1PLA2G2APLA2G2CMEN1
SCHEMBL16199773 1.00 ZDHHC7 (0.51) ZDHHC7ABCB1PLA2G2APLA2G2CMEN1
SCHEMBL11685164 0.98 ABCB1 (0.49) ZDHHC7ABCB1PLA2G2APLA2G2CMEN1
SCHEMBL9731889 0.84 MEN1 (0.60) ZDHHC7ABCB1PLA2G2CMEN1KMT2A
SCHEMBL7153248 0.83 GPR84 (0.52) PLA2G2APLA2G2CMEN1KMT2AASAH1
SCHEMBL8005773 0.83 GPR84 (0.52) PLA2G2APLA2G2CMEN1KMT2AASAH1
SCHEMBL3179420 0.83 GPR84 (0.52) PLA2G2APLA2G2CMEN1KMT2AASAH1
SCHEMBL11681362 0.81 GPR84 (0.48) PLA2G2AMEN1KMT2AASAH1GPR84
SCHEMBL21115798 0.81 ZDHHC7 (0.49) ZDHHC7ABCB1PLA2G2APLA2G2CBIRC2
SCHEMBL12341004 0.78 ZDHHC7 (0.59) ZDHHC7ABCB1MEN1KMT2AASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2796444-B1 METHOD FOR PRODUCING HIGH-PURITY CERAMIDE TAKASAGO PERFUMERY CO LTD (JP) 2017-03-15 EP disclosed
US-9079826-B2 Method for producing high-purity ceramide TAKASAGO INTERNATIONAL CORPORATION (JP) 2015-07-14 US disclosed
US-9079826-B2 Method for producing high-purity ceramide TAKASAGO INTERNATIONAL CORPORATION (JP) 2015-07-14 US disclosed
US-20140364649-A1 METHOD FOR PRODUCING HIGH-PURITY CERAMIDE TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-12-11 US disclosed
US-20140364649-A1 METHOD FOR PRODUCING HIGH-PURITY CERAMIDE TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-12-11 US disclosed
EP-2796444-A1 METHOD FOR PRODUCING HIGH-PURITY CERAMIDE Takasago International Corporation (JP) 2014-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364649-A1 METHOD FOR PRODUCING HIGH-PURITY CERAMIDE CERT1, CERS2, SGMS1 ZDHHC7 58/4885ABCB1 4878/4885PLA2G2A 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.